Latest Research in Carcinoma of the Gastroesophageal Junction

April 4, 2017

This video highlights the latest research in carcinoma of the gastroesophageal junction, including how using genetic information can help guide treatment.

In this video, Ian Chau, MD, of Royal Marsden Hospital in London, highlights the latest research in carcinoma of the gastroesophageal junction, including a look at immunotherapy in this disease, and how using genetic information can help guide treatment with chemotherapy.

In HER2-positive patients, where trastuzumab is standard in the first-line setting, studies are looking at how to optimize the use of this agent. Chau reviews the findings of two second-line studies that tested switching to a different type of chemotherapy after disease progression while continuing on with trastuzumab.